Zymeworks Up 10% On Positive Study Results Of Zanidatamab In Biliary Tract Cancer Treatment

On:

Shares of Zymeworks Inc. (ZYME) are rising more than 10% Monday morning after reporting positive topline results from the Phase 2b study of zanidatamab in patients with biliary tract cancers.

Topline results from the Phase 2b HERIZON-BTC-01 study showed that 41.3% of enrolled patients with HER2-amplified and expressing disease achieved an objective response after treatment with zanidatamab.

Full results from the study are expected to be presented in 2023.

ZYME is at $7.17 currently. It has traded in the range of $4.11-$17.27 in the last 1 year.

Source: Read Full Article

Lates News:
  1. Carvana Up 12%; Gets 'notable S&P Global Ratings Upgrades"
  2. Ali Martinez: Bitcoin in Danger of Falling to $20,590
  3. Data Highlights Massive BTC Accumulation By Whales As 'Extreme Fear' Grips Bitcoin Price
  4. The Memecoin Craze: How BRC-20 Tokens Are Making Their Mark on the Bitcoin Blockchain
  5. On Holding Slips 8% In Spite Of Increased Profit, Sales